PTPIOTCPharmaceutical PreparationsFiscal year ends December 31

Petros Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.00+0.00 (+5.56%)

Close on Oct 19, 2026

Market cap: $135.07K
P/E (TTM): –
Dividend yield: –

Petros Pharmaceuticals, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	5.14	1.72	13	9.43	24	17	2.15
Cash & Short-Term Investments	5.14	1.72	13	9.43	24	17	2.15
Receivables	–	0.42	2.23	2.11	2.46	5.15	–
Inventory	–	1.35	1.61	1.82	0.52	0.76	–
Prepaid Expenses & Other	0.03	0.00	2.03	1.32	3.72	2.85	–
Other Current Assets	–	0.01	0.11	0.14	0.11	0.11	–
Total Current Assets	5.16	7.29	20	15	31	26	–
Property, Plant & Equipment	–	0.02	0.03	0.04	0.05	0.06	–
Operating Lease Right-of-Use Assets	–	0.11	0.23	0.36	0.48	0.58	–
Intangible Assets	–	3.20	8.97	12	25	32	39
Other Long-Term Assets	–	–	–	0.36	0.48	0.58	–
Total Assets	5.16	11	34	32	67	70	–
Accounts Payable	0.08	0.76	1.71	1.81	4.56	–	–
Accrued Expenses	0.14	0.10	5.36	3.63	12	15	–
Current Portion of Long-Term Debt	–	–	–	–	–	7.18	–
Current Debt	–	–	–	–	–	7.18	–
Current Portion of Leases	–	0.06	0.13	0.14	0.13	0.11	–
Other Current Liabilities	–	0.08	0.49	0.54	0.26	0.22	–
Total Current Liabilities	2.29	18	11	7.07	31	42	–
Long-Term Debt	–	–	6.86	8.39	–	–	–
Long-Term Leases	–	0.08	0.14	0.26	0.41	0.53	–
Operating Lease Liabilities	–	0.14	0.26	0.41	0.53	0.64	–
Other Long-Term Liabilities	–	0.08	0.14	0.26	0.41	0.60	–
Total Liabilities	2.29	18	21	16	32	52	–
Total Debt	–	–	6.86	8.39	–	7.18	–
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	–
Additional Paid-In Capital	114	106	111	107	106	79	–
Retained Earnings	-111	-113	-99	-91	-71	-62	–
Shareholders' Equity	2.87	-7.47	12	17	36	17	8.02
Total Equity	2.87	-7.47	12	17	36	17	8.02
Total Liabilities & Equity	5.16	11	34	32	67	70	–
Shares Outstanding(shares)	42	0.42	0.12	0.08	0.08	0.04	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -83.3%

Financial strength

Current ratio: 1.25
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 122.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.19
Dividend yield: –